^Lawler CP (1999). „Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes”.Neuropsychopharmacology.20 (6): 612—27.PMID10327430.doi:10.1016/S0893-133X(98)00099-2.
^Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR (2005). „Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist”.J Pharmacol Exp Ther.315 (3): 1278—87.PMID16135699.doi:10.1124/jpet.105.092155.
^Jordan, S (2002). „The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor”.Eur J Pharmacol.441 (3): 137—140.PMID12063084.doi:10.1016/S0014-2999(02)01532-7.
^Shapiro, DA (2003). „Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology”.Neuropsychopharmacology.28 (8): 1400—1411.PMID12784105.doi:10.1038/sj.npp.1300203.
^Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (2006). „Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms”.Biochem Pharmacol.71 (4): 521—9.PMID16336943.doi:10.1016/j.bcp.2005.11.007.
Y
Н
